Leerink Partners initiated coverage on Laboratory Corp with a new price target
$LH
Medical Specialities
Health Care
Leerink Partners initiated coverage of Laboratory Corp with a rating of Outperform and set a new price target of $260.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/2/2025 | $276.00 | Buy | Redburn Atlantic |
| 3/4/2025 | $250.00 → $300.00 | Neutral → Buy | Citigroup |
| 1/7/2025 | $260.00 → $265.00 | In-line → Outperform | Evercore ISI |
| 12/10/2024 | $265.00 → $275.00 | Buy | Jefferies |
| 10/30/2024 | Hold → Buy | HSBC Securities | |
| 10/1/2024 | $235.00 | Neutral | Piper Sandler |
| 3/25/2024 | $250.00 | Hold → Buy | Argus |
| 2/26/2024 | $260.00 | Outperform | Leerink Partners |
Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00
Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously
Evercore ISI upgraded Labcorp Holdings Inc. from In-line to Outperform and set a new price target of $265.00 from $260.00 previously
New offering delivers convenient, comprehensive lab testing solutions for functional medicine, integrative medicine and primary care providers BURLINGTON, N.C., June 18, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Whole Health Solutions to support the growing needs of functional medicine, integrative medicine and primary care providers in delivering holistic care. The solution launches specialized test panels and a tailored test menu of more than 1,000 scientifically backed biomarkers for cardiometabolic health, hormones, micronutrients, longevity and whole body wellness.
New test offerings target solid tumors and hematologic malignancies Enhanced biopharma services support accelerated clinical trials and companion diagnostic development BURLINGTON, N.C., May 30, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio. The additions include new test offerings for solid tumor and hematologic malignancies and enhanced biopharma solutions designed to accelerate clinical trials and companion diagnostic development. "Labcorp is comm
SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has appointed diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company's continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform. Aicher's expertise in building and scaling diagnostic platforms will be instrumental as SOLVD Health expands its personalized health solutions. He brings more than three decades of executiv
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
144 - LABCORP HOLDINGS INC. (0000920148) (Subject)
144 - LABCORP HOLDINGS INC. (0000920148) (Subject)
SD - LABCORP HOLDINGS INC. (0000920148) (Filer)